- Conditions
- Nasopharyngeal Neoplasms
- Interventions
- CC-486
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 759
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Carbon Monoxide Measurement, Nicotine Oral Pouch, Questionnaire Administration, Smoke usual brand cigarette
- Procedure · Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lung Cancer
- Interventions
- vinorelbine tartrate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 46
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 38 more
- Conditions
- Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
- Interventions
- Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cetuximab, BIBW 2992
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
- Interventions
- CORA- Device:smartphones"
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma
- Interventions
- Cabozantinib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Atlanta, Georgia
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Interventions
- CC-223, erlotinib, CC-223, oral azacitidine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • New York, New York + 4 more
- Conditions
- Non Small Cell Lung Cancer, Cancer
- Interventions
- Venetoclax, Pembrolizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- docetaxel, placebo, nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
- Conditions
- Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
- Interventions
- Metagenomic sequencing, Metabolic analysis
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Interventions
- Panitumumab IRDye 800
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Adenomatous Polyp, Colorectal Carcinoma
- Interventions
- macrogol 3350-based oral osmotic laxative, Placebo, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts
- Conditions
- Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy
- Interventions
- questionnaire administration, quality-of-life assessment, laboratory biomarker analysis, bovine lactoferrin
- Other · Procedure · Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Head and Neck Cancer
- Interventions
- survey administration
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 73
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
- Conditions
- Head and Neck Cancer
- Interventions
- biologic sample preservation procedure, medical chart review
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2050
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Head and Neck Cancer
- Interventions
- capecitabine, oxaliplatin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- NRC-2694-A, Paclitaxel
- Drug
- Lead sponsor
- NATCO Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Fullerton, California • Los Angeles, California • Boca Raton, Florida + 7 more
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Head and Neck Cancer
- Interventions
- EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
- Biological · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Carcinoma
- Interventions
- Best Practice, Oral Cryotherapy, Survey Administration
- Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Head and Neck Cancer
- Interventions
- thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas